Showing results (221-230 of 928) with videos related to
Sort By:
Pageof 93
Frontiers in Psychiatry|April 11, 2022
Attitudes Toward a Pre-authorized Concealed Opioid Taper: A Qualitative Analysis of Patient and Clinician PerspectivesTheresa Bedford, Nkaku Kisaalita, Nathaniel R Haycock, et al.Pain|March 5, 2025
Factors influencing the hypoalgesic effects of virtual realityRoni Shafir, Lakota Watson, Ryan B Felix, et al.Pain|October 14, 2025
Placebo and nocebo effectsBelina Rodrigues, Nandini Raghuraman, Roni Shafir, et al.Depression and Anxiety|November 7, 2006
Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDDAmy Farabaugh, David Mischoulon, Faye Schwartz, et al.Schizophrenia Research|April 13, 2016
Health-related quality of life in acute schizophrenia patients treated with RBP-7000 once monthly risperidone: An 8-week, randomized, double-blind, placebo-controlled, multicenter phase 3 studyJohn J Isitt, Vijay R Nadipelli, Alex Kouassi, et al.Journal of Affective Disorders|July 16, 2008
Predictors of relapse in a study of duloxetine treatment in patients with major depressive disorderMaurizio Fava, Curtis Wiltse, Daniel Walker, et al.Comprehensive Psychiatry|September 24, 2005
Relationships between major depressive disorder and comorbid anxiety and personality disordersAmy Farabaugh, Maurizio Fava, David Mischoulon, et al.Pain|May 1, 2014
The magnitude of nocebo effects in pain: a meta-analysisGitte Laue Petersen, Nanna Brix Finnerup, Luana Colloca, et al.Lancet Regional Health. Americas|February 26, 2026
A critical role of affective content in the analgesic effect of virtual reality: a cross-sectional within-subject studyNandini Raghuraman, Roni Shafir, GianCarlo Colloca, et al.Depression and Anxiety|May 9, 2020
Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorderRoy H Perlis, Daniel Dowd, Maurizio Fava, et al.Pageof 93